Efficacy of Atorvastatin on in-hospital outcome of COVID-19 infection

Efficacy of Atorvastatin on 90 patients in-hospital outcome of COVID-19 infection in boali hospital of Qazvin

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200906048638N1

Enrollment

Registered

2021-02-01

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronavirus/ststin. Clinically-epidemiologically diagnosed COVID-19

Interventions

Intervention 1: Intervention group:atrovastatin 40 mg tablets once a day for 7 days abidi company. Intervention 2: Control group:plasibo once a day for 7 days porsina company.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospitalization in corona-related wards Confirmation of the disease by CT scan or PCR No history of liver failure

Exclusion criteria

Exclusion criteria: Having non-pulmonary fungal and bacterial infections (non-pulmonary, infectious bed sores, etc.) Lack of patient consent to participate in the study Receive treatments other than chloroquine, azithromycin and ceftriaxone History of receiving statins Hypersensitivity reaction or any contraindication to the use of atorvastatin

Design outcomes

Primary

Measure	Time frame
Crp. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Wbc. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Fever. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Tachikardia. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Heart rate. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Bp. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Sa o2. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Bs. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Plt. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.	—

Measure

Time frame

Crp. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Wbc. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Fever. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Tachikardia. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Heart rate. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Bp. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Sa o2. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Bs. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.;Plt. Timepoint: the first, third, fifth day. Method of measurement: questionnaire.

—

Secondary

Measure	Time frame
Quality of life score. Timepoint: The first, third and fifth day. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactass llami

Qazvin University of Medical Sciences

Allami9@yahoo.com+98 28 3333 2930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026